KELIX bio Funding: $200M Raised, Series B (2022)

KELIX bio funding overview

KELIX bio is based in Malta. KELIX bio has raised $200M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series B announced in March 2022. The round record for KELIX bio runs through 2022; nothing later has been disclosed. Investors on record include DPI, British International Investment (BII), European Bank for Reconstruction and Development (EBRD), Proparco, DEG, FMO. 6 distinct backers are named across the disclosed rounds.

KELIX bio at a glance

Total raised: $200M
Latest round: Series B
Latest round date: March 2022
Headquarters: Malta
Notable investors: DPI, British International Investment (BII), European Bank for Reconstruction and Development (EBRD), Proparco, DEG, FMO

Frequently asked about KELIX bio funding

How much has KELIX bio raised?: KELIX bio has raised $200M in total disclosed funding across the rounds on record.
Who has invested in KELIX bio?: DPI, British International Investment (BII), European Bank for Reconstruction and Development (EBRD), Proparco, DEG, FMO are named among the investors backing KELIX bio.
What was the latest KELIX bio funding round?: The most recent disclosed round is a Series B, announced in March 2022.
Where is KELIX bio based?: KELIX bio is based in Malta.
When did KELIX bio last raise?: The last disclosed KELIX bio round closed in March 2022 at Series B.

We update the KELIX bio record whenever a new round is filed or announced, so the totals above track the public record rather than estimates. Related companies in Malta and their backers are listed below.

KELIX bio Funding: $200M Raised, Series B (2022)

KELIX bio funding overview

KELIX bio at a glance

Frequently asked about KELIX bio funding

Companies related to KELIX bio (36)

Browse related funding lists (6)